肿瘤学：Treatment-related neutropenia as predictor of response to adjuvant palbociclib in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).
原文摘录：BACKGROUND: Prior analyses of PALLAS (NCT02513394), a phase III trial that randomized patients with stage II-III hormone receptor-positive breast cancer to receive adjuvant palbociclib plus endocrine therapy (ET) or ET alone, did not show benefit of the c … gov, NCT02513394
关注理由：这条肿瘤学内容涉及随机对照研究，建议同时核对纳入人群、主要终点与报告结果。